Denali Therapeutics Inc. DNLI Option Fee Payment — Total collaboration revenue

Other product segments

Similar metrics at other companies

ESP

ESPRCollaboration revenue — Total Revenues

$36.71M+22.0%

SUPNCollaboration revenue (ZURZUVAE) — Total revenues

$27.64M—

CYTKCollaboration Revenues — Revenue

$3.29M+36.2%

EXELCollaboration — Total revenues

$55.67M+15.4%

NBIXCollaboration revenues — Total revenues

$3.5M-60.7%

PTH

PTHSLicense and collaboration revenues — Total Revenue

$241K—

FAQ

What is Denali Therapeutics Inc.'s option fee payment — total collaboration revenue?

Denali Therapeutics Inc. (DNLI) reported option fee payment — total collaboration revenue of $2.5M in Q4 2026.

How has Denali Therapeutics Inc.'s option fee payment — total collaboration revenue changed year-over-year?

Denali Therapeutics Inc.'s option fee payment — total collaboration revenue increased by 100.0% year-over-year, from $1.25M to $2.5M.

What is the long-term trend for Denali Therapeutics Inc.'s option fee payment — total collaboration revenue?

Over 3 years (2022 to 2026), Denali Therapeutics Inc.'s option fee payment — total collaboration revenue has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.

What does option fee payment — total collaboration revenue mean?

This metric represents the revenue recognized from option fees associated with collaborative research and development agreements. It reflects the financial value generated when partners exercise rights or pay for the privilege to access the company's proprietary technology platforms or specific therapeutic programs. This revenue stream is a key indicator of the commercial interest in the company's early-stage pipeline and the monetization of its intellectual property through strategic partnerships.